Wird geladen...
mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment
Mammalian target of rapamycin (mTOR) is a central mediator of cancer cell growth, but it also directs immune cell differentiation and function. On this basis, we have explored the hypothesis that mTOR inhibition can enhance cancer immunotherapy. Here we report that a combination of αCD40 agonistic a...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3116937/ https://ncbi.nlm.nih.gov/pubmed/21540234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-3968 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|